Dr. Rashmi Verma, MD

Dr. Verma practices at UC Davis Medical Center in Sacramento, California, part of University of California Health.

Dr. Verma's NPI, 1790919512, was assigned on May 7, 2009. Dr. Verma graduated from Delhi University College of Medical Sciences in 1994. Dr. Verma holds California license A117656.

Dr. Verma's primary practice is UC Davis Medical Center, at 2315 Stockton Boulevard, Sacramento, CA 95817 in Sacramento County. The practice phone is (916) 734-2011.

Dr. Verma's primary practice is UC Davis Medical Center in Sacramento, California, part of University of California Health. Dr. Verma is also affiliated with Enloe Health. The medical group on file is UC Davis Medical Group. Dmand AI also links Dr. Verma to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Verma practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Verma's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Verma is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Verma's licenses on file in 6 states: California, Texas, New York, Arkansas, New Jersey and South Dakota.

Dmand AI lists chronic anemia, colorectal cancer, lymphoma and prostate cancer among the conditions Dr. Verma treats.

CMS data shows 1,008 Medicare services from Dr. Verma across 6 procedure codes in 2024, for 201 Medicare patients. Medicare paid $63,804 for them.

CMS counts 201 Medicare patients who saw Dr. Verma in 2024. The largest group is 75 to 84, with 81 patients. 75% of them have cancer, and 75% have high blood pressure. 34% are also on Medicaid. Their average risk score is 2.64, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Verma's median patient age at 67, with 27% women.

In 2024, Dr. Verma wrote 831 Medicare Part D claims for 108 patients. 71% of them were for generic drugs. CMS names the drug for 693 of them, across 18 drugs with 11 or more claims each, at $2,321,242 in total drug cost. In 2023, CMS named 696 claims across 16 drugs.

Dr. Verma accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Verma as offering telehealth.

Dmand AI links 50 papers to Dr. Verma, published from 2011 to 2025. 2022 was the busiest year, with 6. The most frequent topics are Breast Neoplasms, Antigens, CD and COVID-19. Dr. Verma has published most often in Cureus. Dr. Verma's most frequent co-authors are Jose A. Figueroa, MD, Samuel Michael Gelnick, MD and Amardeep Singh Aulakh, DO.

Dmand AI links Dr. Verma to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Prostatic Neoplasms and Prostatic Diseases.

CMS Open Payments shows 118 general payments to Dr. Verma from 26 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 54% of the total. Janssen Pharmaceuticals, Inc paid the most, $1,654.

Dmand AI lists 3 awards for Dr. Verma, most recently Chief Fellow, Hematology and Oncology in 2016.

Dr. Verma graduated from Delhi University College of Medical Sciences in 1994. Dr. Verma is a member of ACP, ASCO, ASH, Texas Indo American Physicians Association, TMA and Texas Society of Clinical Oncology.

Dr. Verma is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.